Skip to main content
SinoMab BioScience Limited logo

SinoMab BioScience Limited — Investor Relations & Filings

Ticker · 3681 ISIN · HK0000544194 LEI · 9845009B6CEEC4694006 HKEX Manufacturing
Open in API
Filings indexed 320 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country HK Hong Kong
Listing HKEX 3681

About SinoMab BioScience Limited

http://www.sinomab.com

SinoMab BioScience Limited is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of therapeutic antibodies. The company focuses on developing novel, highly efficacious drugs, including "first-in-class" and "best-in-class" candidates, primarily for the treatment of immunological and life-threatening diseases, such as rheumatoid arthritis. SinoMab maintains full-spectrum drug development capabilities, covering antibody re-engineering, bioprocessing, and manufacturing, aimed at addressing significant unmet medical needs globally.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Regulatory Filings Classification · 95% confidence The document is the HKEX monthly return (Form FF301) for movements in securities (issued shares, share options, public float, etc.) submitted by a listed issuer to the Stock Exchange of Hong Kong. It is a routine regulatory compliance filing under the Listing Rules rather than a financial report (e.g., annual, interim, earnings) or an announcement of corporate actions like dividends or M&A. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-06-04 English
VOLUNTARY ANNOUNCEMENT PRESENTATION OF PRECLINICAL STUDIES OF ANTI-CGC ANTIBODY (hC2) AT SID ANNUAL MEETING 2026
Regulatory Filings Classification · 30% confidence The document is a voluntary corporate announcement regarding the presentation of preclinical study results at a scientific conference. It contains no financial statements, no management changes, no voting results, and is not an investor deck or earnings release. It simply notifies the market of a scientific poster presentation and related abstract link. This does not fit any specific category (e.g., 10-K, IR, ER, IP, etc.), so it falls under the general Regulatory Filings (RNS) fallback category.
2026-05-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing (Form FF301) submitted to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for SINOMAB BIOSCIENCE LIMITED for the month ended 30 April 2026. It details movements in issued shares, treasury shares, share options, and public float sufficiency confirmation. The document is a regulatory compliance report related to share capital and securities movements, not a financial report, earnings release, or management discussion. It is a regulatory announcement required by the exchange listing rules, fitting the category of Regulatory Filings (RNS). The document length is 9167 characters, which is substantive but the content is clearly a regulatory compliance return rather than a financial or management report.
2026-05-06 English
2025 Environmental, Social and Governance Report
Environmental & Social Information Classification · 90% confidence The document is titled “2025 Environmental, Social and Governance Report” and contains detailed disclosures of ESG performance (environmental KPIs, social responsibility, governance structure, materiality analysis, stakeholder engagement, etc.) prepared according to the ESG Reporting Code of the Hong Kong Stock Exchange. It is a full report on ESG matters, not merely an announcement. Therefore, it falls under Environmental & Social Information.
2026-04-27 English
Notification Letter to Non-registered Shareholders and Reply Form
Report Publication Announcement Classification · 90% confidence The document is a notification letter to non-registered holders informing them that the 2025 Annual Report and Circular containing the Notice of Annual General Meeting have been published on the HKExnews and company websites, and provides instructions for accessing or requesting printed copies. It does not contain the full Annual Report or AGM Circular itself but merely announces their publication. This fits the definition of a Report Publication Announcement (RPA).
2026-04-27 English
Notification Letter to Registered Shareholders and Reply Form
Report Publication Announcement Classification · 93% confidence The document is a shareholder letter notifying the publication of the Company’s 2025 Annual Report, Circular, AGM Notice, and Proxy Form on the HKExnews and Company websites. It provides instructions on how to access or request printed copies and solicits electronic consent for future corporate communications. It does not contain the actual financials or management discussion itself but merely announces the availability of these materials. Therefore, per the “menu vs meal” rule, it is a Report Publication Announcement (RPA).
2026-04-27 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.